Subgroup analysis of ROCKET AF trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) showed similar beneficial effect of rivaroxaban in patients with or without previous stroke or TIA [8]. Here, F10 is linked to atrial fibrillation.